Abstract

Personalized medicine means creatingprecise treatment plans for individuals based on pharmacogenetic and pharmacogenomics data. The practicalities of personalized medicine can be examined by adopting various methods including single nucleotide polymorphism genotyping. In future perspectives, the molecular diagnostics will playkey role in the improvement of personalized medicine, by combination of treatment and diagnosis. In present scenario, there are many examples of personalized medicine, like selecting patients for cancer treatment based on genotype to avoid non-responders or side effects. Selftreatment is economically viable because it reduces drug development costs by shortening the time to drug development. Incorporating pharmacogenomics into clinical trials reduces the likelihood of clinical trial failure and leads to safer, more effective treatments for specific patients. Some of the advantages and challenges of developing personalized medicine are reviewed.The concept of personalized medicine was not new at the time, but it was made possible in the 1990s by advances in DNA sequencing technology, including automation and amplification. The advent of personalized medicine has accelerated the development of health information technology, which involves the electronic processing and storage of patient information. Advances in these areas, especially the use of electronic health records (EHRs) that store patients’ medical histories, medications, test results, and demographic information, are important for integrating data from genetic and genomic studies into clinical settings.

• 1.   https://www.britannica.com/science/ personalized-medicine/accessed on 01-11-2024.
• 2.   Singh S., Ernst E. (2008). Trick or Treatment: Alternative Medicine on Trial. London: Bantam. ISBN 978-0593061299.
• 3.   Bowers B.S., ed. (2007). The Medieval Hospital and Medical Practice. Ashgate. p. 258. ISBN 978-0-7546 5110-9.
• 4.   Stratified, personalized or P4 medicine: A new direction for placing the patient at the center of healthcare and health education (Technical report). Academy of Medical Sciences. May 2015. Archived from the original on 27 October 2016. Retrieved 6 January 2016.
• 5.   Egnew T.R. (1 March 2009). “Suffering, meaning, and healing: challenges of contemporary medicine”. Annals of Family Medicine. 7 (2): 170–5. doi:10.1370/afm.943. PMC 2653974. PMID 19273873.
• 6.   “The Case for Personalized Medicine” (PDF). Personalized Medicine Coalition. 2014. Retrieved 6 January 2016.
• 7.   Smith R. (15 October 2012). “Stratified, personalised, or precision medicine”. British Medical Journal. Retrieved 6 January 2016.
• 8.   Lesko L.J. (June 2007). “Personalized medicine: elusive dream or imminent reality?”. Clinical Pharmacology and Therapeutics. 81 (6): 807–16. doi:10.1038/sj.clpt.6100204. PMID 17505496. S2CID 17860973.
• 9.   Priyadharshini V.S., Teran L.M. (2016). “Personalized Medicine in Respiratory Disease”. Chapter Five - Personalized Medicine in Respiratory Disease: Role of Proteomics. Advances in Protein Chemistry and Structural Biology. Vol. 102. pp. 115–146. doi:10.1016/bs.apcsb.2015.11.008. ISBN 978-0-12-804795-8. PMID 26827604.
• 10.   Xie J., Lee S., Chen X. (August 2010). Donev R. (ed.). “Nanoparticle-based theranostic agents”. Advanced Drug Delivery Reviews. Personalized Medicine. 62 (11). Academic Press: 1064–79. doi:10.1016/j.addr.2010.07.009. PMC 2988080. PMID 20691229.

Data Sharing Statement

Funding